用于达普罗多斯塔特的模型信息药物开发支持在慢性脏病患者贫血患者中设计个性化剂量方案
Kelly M Mahar1, Shuying Yang2, Brendan Johnson3
1GSK, Collegeville, Pennsylvania, USA.
Clinical pharmacology and therapeutics
|November 1, 2025
概括
基于模型的药物开发 (MIDD) 优化了慢性脏病中贫血的达普罗德斯塔特剂量. 定量方法指导剂量选择和个性化为患者的利益.
科学领域:
- 制药指标 (Pharmacometrics) 是一个指标.
- 药物开发 药物开发
- 临床药理学 临床药理学
背景情况:
- 慢性病 (CKD) 中的贫血是一种显著的并发症.
- 催氧诱导因子酸酶 (HIF-PHI) 抑制剂提供了一种新的治疗方法.
- 达普罗杜沙特是一种口服的HIF-PHI抑制剂,用于治疗慢性病患者的贫血.
研究的目的:
- 为了说明模型信息化药物开发 (MIDD) 在 daprodustat.ustat 的开发和监管批准中的关键作用.
- 展示综合定量方法如何指导剂量策略和剂量个性化.
- 展示MIDD在告知III期试验设计和监管相互作用中的应用.
主要方法:
- 纵向血红蛋白反应建模以预测治疗结果.
- 种群药动力学 (PopPK) 分析,以了解不同患者群体的药物行为.
- 临床试验模拟以优化剂量方案和评估试验设计.
主要成果:
- MIDD在选择达普罗德斯塔特的最佳III期剂量方面发挥了重要作用.
- 定量建模促进了有效剂量个性化,确保了针对患者的具体治疗.
- 综合方法支持成功的监管提交和批准.
结论:
- 基于模型的药物开发是优化新疗法开发的强大策略,例如: daprodustat.stat.
- 定量工具对于指导临床试验设计,剂量选择和监管决策至关重要.
- 对达普罗杜斯塔特的MIDD的成功应用凸显了其在为患者提供有效的CKD贫血治疗的价值.
相关概念视频
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
202
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
202
01:28Dosage Regimens: Designs and Approaches
250
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
250
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
182
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
182
01:25Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance
176
In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance...
176
01:11Renal Failure: Dose Adjustments
426
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
426
01:28Chronic Kidney Disease III: Interprofessional Care
332
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
332